Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors.

Abstract

To combat the public health threat from emerging coronaviruses (CoV), the development of antiviral therapies with either virus-specific or pan-coronaviral activities is necessary. An important step in antiviral drug development is the screening of potential inhibitors in cell-based systems. The recent emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) necessitates adapting methods that have been used to identify antivirals against severe acute respiratory syndrome coronavirus (SARS-CoV) and developing new approaches to more efficiently screen antiviral drugs. In this article we review cell-based assays using infectious virus (BSL-3) and surrogate assays (BSL-2) that can be implemented to accelerate antiviral development against MERS-CoV and future emergent coronaviruses. This paper forms part of a series of invited articles in Antiviral Research on "From SARS to MERS: 10years of research on highly pathogenic human coronaviruses."

• Authors: Andy Kilianski, Susan C Baker
• Journal: Antiviral research (Antiviral Res) Vol. 101 Pg. 105-12 (Jan 2014) ISSN: 1872-9096 [Electronic] Netherlands
• PMID: 24269477 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
• Copyright: Copyright © 2013 Elsevier B.V. All rights reserved.

Chemical References

• Antiviral Agents

Topics

• Animals
• Antiviral Agents (isolation & purification, pharmacology)
• Cell Line
• Coronavirus (drug effects)
• Drug Evaluation, Preclinical (methods)
• Humans